AtaiBeckley Inc.

NasdaqGM:ATAI Stock Report

Market Cap: US$1.2b

AtaiBeckley Valuation

Is ATAI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ATAI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ATAI ($3.4) is trading below our estimate of future cash flow value ($16.76)

Significantly Below Future Cash Flow Value: ATAI is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATAI?

Key metric: As ATAI barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ATAI. This is calculated by dividing ATAI's market cap by their current book value.
What is ATAI's PB Ratio?
PB Ratio5.6x
BookUS$221.87m
Market CapUS$1.22b

Price to Book Ratio vs Peers

How does ATAI's PB Ratio compare to its peers?

The above table shows the PB ratio for ATAI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.4x
TARS Tarsus Pharmaceuticals
8.3x51.10%US$2.8b
LXRX Lexicon Pharmaceuticals
5.9x29.19%US$699.1m
NUVB Nuvation Bio
4.5x53.89%US$1.5b
SEPN Septerna
2.7x-28.11%US$1.1b
ATAI AtaiBeckley
5.6x48.27%US$1.2b

Price-To-Book vs Peers: ATAI is expensive based on its Price-To-Book Ratio (5.6x) compared to the peer average (5.4x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does ATAI's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

21 CompaniesPrice / BookEstimated GrowthMarket Cap
CTXR Citius Pharmaceuticals
0.2x43.71%US$16.09m
CPHI China Pharma Holdings
0.4xn/aUS$3.21m
INM InMed Pharmaceuticals
0.3xn/aUS$2.67m
CMND Clearmind Medicine
0.3xn/aUS$2.05m
ATAI 5.6xIndustry Avg. 2.1xNo. of Companies25PB01.63.24.86.48+
21 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ATAI is expensive based on its Price-To-Book Ratio (5.6x) compared to the US Pharmaceuticals industry average (2.1x).

Price to Book Ratio vs Fair Ratio

What is ATAI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATAI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ATAI's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ATAI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.40
US$13.33
+292.16%
32.31%US$25.00US$7.00n/a12
Mar ’27US$3.63
US$12.45
+243.10%
21.75%US$16.00US$7.00n/a11
Feb ’27US$3.76
US$12.27
+226.40%
21.72%US$16.00US$7.00n/a11
Jan ’27US$4.09
US$12.40
+203.18%
22.29%US$16.00US$7.00n/a10
Dec ’26US$3.84
US$12.00
+212.50%
21.87%US$16.00US$7.00n/a9
Nov ’26US$5.84
US$12.11
+107.38%
20.02%US$16.00US$8.00n/a9
Oct ’26US$5.20
US$11.29
+117.03%
27.50%US$16.00US$7.00n/a7
Sep ’26US$4.58
US$11.29
+146.41%
27.50%US$16.00US$7.00n/a7
Aug ’26US$4.17
US$11.29
+170.64%
27.50%US$16.00US$7.00n/a7
Jul ’26US$2.71
US$9.20
+239.48%
25.16%US$12.00US$6.00n/a5
Jun ’26US$2.31
US$8.00
+246.32%
31.87%US$11.00US$5.00n/a4
May ’26US$1.47
US$8.00
+444.22%
31.87%US$11.00US$5.00n/a4
Apr ’26US$1.24
US$8.00
+545.16%
31.87%US$11.00US$5.00n/a4
Mar ’26US$1.72
US$8.00
+365.12%
31.87%US$11.00US$5.00US$3.634
Feb ’26US$1.55
US$8.00
+416.13%
31.87%US$11.00US$5.00US$3.764
Jan ’26US$1.33
US$8.00
+501.50%
31.87%US$11.00US$5.00US$4.094
Dec ’25US$1.78
US$8.00
+349.44%
31.87%US$11.00US$5.00US$3.844
Nov ’25US$1.08
US$9.25
+756.48%
43.50%US$15.00US$5.00US$5.844
Oct ’25US$1.12
US$9.25
+725.89%
43.50%US$15.00US$5.00US$5.204
Sep ’25US$1.30
US$9.25
+611.54%
43.50%US$15.00US$5.00US$4.584
Aug ’25US$1.42
US$9.50
+569.01%
39.74%US$15.00US$6.00US$4.174
Jul ’25US$1.35
US$11.80
+774.07%
48.36%US$21.00US$6.00US$2.715
Jun ’25US$1.57
US$11.80
+651.59%
48.36%US$21.00US$6.00US$2.315
May ’25US$2.05
US$11.80
+475.61%
48.36%US$21.00US$6.00US$1.475
Apr ’25US$1.86
US$14.50
+679.57%
43.21%US$21.00US$6.00US$1.244
Mar ’25US$2.13
US$12.62
+492.49%
53.47%US$21.00US$5.10US$1.725
US$13.33
Fair Value
74.5% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/30 04:46
End of Day Share Price 2026/03/30 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AtaiBeckley Inc. is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BoucheyAegis Capital Corporation
Harry GillisBerenberg
Samuel EnglandBerenberg